Catalyst Monitor December 2016

07 November 2016

This report compiles published predictive intelligence based on interviews with key opinion leaders on market-moving events expected to occur during the next month and current quarter. It includes coverage on Roche’s ocrelizumab for RRMS and PPMS, Ophthotech’s Fovista for wet agerelated macular degeneration, Aradigm’s pulmaquin for non-cystic fibrosis bronchiectasis and other key situations.